letolizumab (BMS-986004) / BMS - LARVOL DELTA

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Nov 2022 ➔ Sep 2023 | Trial primary completion date: Nov 2022 ➔ Sep 2023

Trial completion date • Trial primary completion date • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • HLA-B • HLA-C • HLA-DRB1

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Nov 2022 | Trial primary completion date: Sep 2023 ➔ Nov 2022

Trial completion • Trial completion date • Trial primary completion date • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • HLA-B • HLA-C • HLA-DRB1

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2024 ➔ Sep 2024 | Trial primary completion date: Jan 2024 ➔ Sep 2023

Enrollment closed • Trial completion date • Trial primary completion date • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • HLA-B • HLA-C • HLA-DRB1

CD40 Ligand Blockade Prevents Acute Gvhd: Results from a Multicenter Phase I-Ib Trial (TCT-ASTCT-CIBMTR 2022) - P1 | "Included subjects received 8/8 HLA matched unrelated donor peripheral blood stem cell HCT, and sirolimus/tacrolimus GVHD prophylaxis...TMA was uncommon (n=1), and hepatic VOD/SOS cases (n=4) occurred in the setting of myeloablative busulfan/fludarabine conditioning...Addition of BMS-986004 to standard prophylaxis is safe, and has activity in prevention of GVHD. Additional planned analyses will examine late post-HCT outcomes and interrogate biologic effect of the intervention."

Clinical • P1 data • Acute Graft versus Host Disease • Cardiovascular • CNS Disorders • Epilepsy • Graft versus Host Disease • Immune Modulation • Immunology • Infectious Disease • Inflammation • Transplantation • CD19 • CD40LG • CD8

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P1/2 ➔ P1

Phase classification • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • HLA-B • HLA-C • HLA-DRB1

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (clinicaltrials.gov) - P1/2; N=40; Recruiting; Sponsor: Bristol-Myers Squibb; Not yet recruiting -> Recruiting

Enrollment open • Biosimilar • Hematological Malignancies • Immunology • Inflammation

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - P1/2; N=45; Recruiting; Sponsor: H. Lee Moffitt Cancer Center and Research Institute; Not yet recruiting ➔ Recruiting; Initiation date: May 2019 ➔ Jan 2019; Trial primary completion date: Dec 2022 ➔ Jan 2024

Enrollment open • Trial initiation date • Trial primary completion date